Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
|Articles|September 16, 2008
- July15 2003
- Volume 10
- Issue 13
Pay Yourself First
Advertisement
There are some indications that the stock market may be coming out of its doldrums. Don't celebrate just yet, doctors. Your best bet is to forget about market movements for the time being and focus on saving all the money you can. Today's physicians—beaten up by market gyrations and falling incomes— should be saving at least 10% of their annual salaries. Wise financial advisors say this is the only way to ensure a comfortable retirement. Just consider what the following monthly savings (assuming a reasonable 8% annual return) will get you in your retirement kitty:
Articles in this issue
about 18 years ago
Less Time, More Workabout 18 years ago
One Hand Giving, Another Taking?about 18 years ago
RIP-Steven C. Campabout 18 years ago
ADDING TO THE MIXabout 18 years ago
SPAMMER SLAMMEDabout 18 years ago
AUDITING THE WEALTHYabout 18 years ago
UNDER THE IRS GUNabout 18 years ago
MEDICARE RUNAROUNDabout 18 years ago
REFINANCING & TAXESabout 18 years ago
WHERE HMO $ GOESAdvertisement
Related to this article
An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
Long-term extension data show iptacopan held a −3.49 mL/min/1.73 m² per year eGFR slope over 48 months, with benefit emerging after patients switched from placebo.
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
Final 96-week phase 1b data show sustained UPCR reduction and stable eGFR about 1.5 years after the last mezagitamab dose, with no serious adverse events.
Final VISIONARY data show sibeprenlimab held eGFR steady over 24 months, with a 4.5 mL/min/1.73 m² per year slope advantage and fewer kidney outcome events vs placebo.
Jonathan Barratt, PhD, FRCP, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack final ORIGIN 3 eGFR data for atacicept in IgAN.
In phase 3 INTREPID, lutikizumab beat placebo on HiSCR75 at week 16 and met all 8 ranked secondary end points in moderate to severe HS.
Advertisement
Advertisement
Trending on HCPLive
1
Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA
2
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
3
AAD's New HS Guidelines Flag 'Step Therapy' as Top Barrier to Care
4
Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes
5